Screener
Icahn Enterprises IEP Pharma — Cash And Cash Equivalents At Carrying Value
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Cash and cash equivalents | $13 | $737 | $24 | $8 | $34 | $2 | $22 | $381 | $1,221 |
| Cash held at consolidated affiliated partnerships and restricted cash | 1,790 | — | 10 | — | 2 | 2 | — | 167 | 1,971 |
| Investments | 1,388 | 12 | — | — | 98 | — | — | — | 1,498 |
| Accounts receivable, net | — | 327 | 29 | 67 | 13 | 27 | 25 | — | 488 |
| Related party note receivable | — | — | — | — | 136 | — | — | — | 136 |
| Inventories, net | — | 603 | 161 | 105 | — | 86 | 23 | — | 978 |
| Property, plant and equipment, net | — | 2,282 | 366 | 148 | 765 | 52 | — | 3 | 3,616 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — cash and cash equivalents at carrying value?
- Icahn Enterprises (IEP) reported pharma — cash and cash equivalents at carrying value of $22M in Q2 2026.
- How has Icahn Enterprises's pharma — cash and cash equivalents at carrying value changed year-over-year?
- Icahn Enterprises's pharma — cash and cash equivalents at carrying value decreased by 33.3% year-over-year, from $33M to $22M.
- What is the long-term trend for Icahn Enterprises's pharma — cash and cash equivalents at carrying value?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — cash and cash equivalents at carrying value has grown at a 39.4% compound annual growth rate (CAGR), from $36M to $136M.
- What does pharma — cash and cash equivalents at carrying value mean?
- Represents the highly liquid assets held by the Pharma segment that can be readily converted into cash to meet short-term obligations. This metric serves as a measure of the segment's immediate financial flexibility and liquidity position. It indicates the segment's ability to fund internal projects or respond to unforeseen operational needs.
Ask your AI about Icahn Enterprises's pharma — cash and cash equivalents at carrying value.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude